NASDAQ: XAGELongevity Health Holdings Inc Stock
$0.16-0.01 (-5.88%)
Updated May 5, 2025
XAGE Price
$0.16
Fair Value Price
-$0.00
Market Cap
$4.91M
52 Week Low
$0.10
52 Week High
$2.93
P/E
-0.33x
P/B
-1.04x
P/S
118.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$50.32k
Earnings
-$10.37M
Gross Margin
87.4%
Operating Margin
-20,740.24%
Profit Margin
-20,605.5%
Debt to Equity
-1.31
Operating Cash Flow
-$4M
Beta
0.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XAGE Overview
Alpha Healthcare Acquisition Corp. III is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations with one or more businesses. Ittargets the healthcare sector in the U.S. The company was incorporated in 2021 and is based in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XAGE's potential to beat the market
- XAGE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important XAGE news, forecast changes, insider trades & much more!
XAGE News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XAGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XAGE ($0.16) is overvalued by 6,356.61% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XAGE ($0.16) is not significantly undervalued (6,356.61%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XAGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XAGE due diligence checks available for Premium users.
Valuation
XAGE fair value
Fair Value of XAGE stock based on Discounted Cash Flow (DCF)
Price
$0.16
Fair Value
-$0.00
Undervalued by
6,241.46%
XAGE ($0.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XAGE ($0.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XAGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XAGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.33x
Industry
37.35x
Market
29.04x
XAGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.04x
Industry
3.96x
XAGE's financial health
Profit margin
Revenue
$17.5k
Net Income
-$914.3k
Profit Margin
-5,230.8%
XAGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XAGE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.5M
Liabilities
$6.2M
Debt to equity
-1.31
XAGE's short-term liabilities ($5.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XAGE's short-term assets ($955.55k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XAGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XAGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$772.1k
Investing
$0.0
Financing
-$208.1k
XAGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XAGE vs Medical Device Stocks
Longevity Health Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.